Patent intelligence · US
US 11230537
Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[2-oxopyridin-1-yl)methyl]phenyl} methyl)pyrazole-4-carboxamide as iallikrein inhibitors
Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[2-oxopyridin-1-yl)methyl]phenyl} methyl)pyrazole-4-carboxa…
Patent details — US 11230537
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 25, 2022
- Expiration
- Jan 20, 2042
- Applicant
- KalVista Pharmaceuticals Limited
- Claims
- 11
- CPC classes
- A61P, A61P1/04, A61P1/18, A61P11/00
Quick answer
US 11230537 (Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[2-oxopyridin-1-yl)methyl]phenyl} methyl)pyrazole-4-carboxamide as iallikrein inhibitors) is held by KalVista Pharmaceuticals Limited. Status: granted. Granted Jan 25, 2022. Expires Jan 20, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- KalVista Pharmaceuticals Limited
- Grant date
- Expiration
- Claims
- 11
- CPC classes
- A61P, A61P1/04, A61P1/18, A61P11/00, A61P13/12, A61P19/02
More from KalVista Pharmaceuticals Limited
Related pharmaceutical patents in our USPTO index.
-
US 11739068
Polymorphs of N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide and salts thereof
granted -
US 11613527
Enzyme inhibitors
granted -
US 11584735
Solid forms of a plasma kallikrein inhibitor and salts thereof
granted -
US 11242333
Inhibitors of plasma kallikrein
granted -
US 11234939
Dosage forms comprising a plasma kallikrein inhibitor
granted -
US 11198691
N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors
granted -
US 11180484
Pyrazole derivatives as plasma kallikrein inhibitors
granted
Frequently asked questions
What is US patent 11230537?
US 11230537 (Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[2-oxopyridin-1-yl)methyl]phenyl} methyl)pyrazole-4-carboxamide as iallikrein inhibitors) is held by KalVista Pharmaceuticals Limited. Status: granted. Granted Jan 25, 2022. Expires Jan 20, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11230537?
KalVista Pharmaceuticals Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 24 pharmaceutical patents for this assignee.
When does US 11230537 expire?
Our index shows an expiration date of Jan 20, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.